DR. STEPHEN MARK FEINSTONE, M.D.
Osteopathic Medicine at Cathedral Ave, Washington, DC

5622861, Apr 22, 1997

Aug 5, 1994

8/287001

Gerardo Kaplan - Rockville MD
Stephen M. Feinstone - Washington DC

The United States of America as represented by the Department of Health
and Human Services - Washington DC

C12N 510, C12N 1512

4352523

Provided is the discovery and isolation of a cellular receptor for hepatitis A virus. Also provided is an isolated nucleic acid molecule comprising a nucleic acid encoding a polypeptide having the biological activity of a hepatitis A virus receptor. Also provided are vectors comprising the isolated nucleic acids encoding a hepatitis A virus receptor in host suitable for expression of the nucleic acids encoding the hepatitis receptor, fragments of the hepatitis A virus receptor, or homologs of the hepatitis A virus receptor. Further provided is a nonhuman transgenic animal which expresses a hepatitis A virus receptor, but does not express an endogenous, active hepatitis A virus receptor. Also provided is a method for screening drugs or vaccines utilizing the transgenic animal expressing a hepatitis A virus receptor. Also provided are methods for use of the purified hepatitis A virus receptor, such as separating hepatitis A virus from blood or other samples, detecting the presence of hepatitis A virus in a sample, determining the anti-hepatitis A virus binding of a compound, preventing hepatitis A virus infection in a subject, or treating a subject infected with hepatitis A virus.

5104792, Apr 14, 1992

Dec 21, 1989

7/454171

Jonathan Silver - Bethesda MD
Stephen Feinstone - Washington DC

The United States of America as represented by the Department of Health
and Human Services - Washington DC

C12Q 168, C07H 1512, C12N 1500

435 6

A modification of the PCR technique is described which allows fragments of RNA or DNA to be amplified without prior knowledge of their sequence. The technique can be used to amplify viral nucleic acids present in small amounts in clinical material allowing, for example, the diagnosis of a particular virus infection or the discovery of new viruses.

2006005, Mar 9, 2006

Aug 26, 2005

11/212258

Deborah Taylor - Frederick MD, US
Stephen Feinstone - Washington DC, US
Montserrat Puig - Bethesda MD, US
Kathleen Mihalik - Oak Hill VA, US

A61K 39/12, C12N 7/00, C12N 15/86

424199100, 435456000, 435235100

Methods for enhancing the production of viral vaccines in cell culture are described, as are the cell cultures. These methods rely on the suppression of the levels of ADAR1 in interferon-deficient cells. The methods comprise (a) infecting a cell culture with a donor virus, wherein said cell culture is an interferon-deficient cell culture that is deficient in ADAR1 activity; (b) culturing said infected cell culture under conditions sufficient to provide efficient virus growth; and (c) harvesting the virus produced.

4620978, Nov 4, 1986

Sep 19, 1984

6/652067

Richard J. Daemer - Washington DC
Stephen M. Feinstone - Washington DC
Ian D. Gust - Fairfield, AU
Robert H. Purcell - Boyds MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

A61K 3929

424 89

Human hepatitis A virus (HAV) can be purified by a process in which master seed lots of HM-175 strain of hepatitis A virus are prepared from triply cloned virus by terminal dilution at passage level about 20 or preferably at least 20-30. The clones tested induced minimal or no hepatitis although significant antibody response was provoked in inoculated primates. A method of preparing the triply cloned inoculum is also described.

5837260, Nov 17, 1998

Jun 7, 1995

8/473304

Jeffrey I. Cohen - Brighton MA
Robert H. Purcell - Boyds MD
Stephen M. Feinstone - Washington DC
John R. Ticehurst - Bethesda MD

The United of America as represented by the Department of Health and
Human Services - Washington DC

A61K 3929, A61K 3912, C12N 700, C12N 704

4242261

A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.

5516630, May 14, 1996

Nov 6, 1991

7/788262

John R. Ticehurst - Kensington MD
David Baltimore - New York NY
Stephen M. Feinstone - Washington DC
Robert H. Purcell - Boyds MD
Vincent R. Racaniello - Scotch Plains NJ
Bahige M. Baroudy - Cincinnati OH

The United States of America as represented by the Department of Health
and Human Services - Washington DC

C12Q 170

435 5

Methods for producing HAV cDNA, products thereof, and uses thereof, are described. HAV cDNA is produced, for example, by reverse transcribing HAV RNA and subsequently inserting the HAV cDNA into bacterial plasmids by genetic-engineering techniques. Transformed bacteria are then cloned and cultured to produce replicated chimetic plasmids containing the HAV cDNA. Such HAV cDNA is useful in assaying for the presence of HAV and in the production of HAV antigen and in the production of antibodies against HAV.

4636469, Jan 13, 1987

Dec 26, 1984

6/686524

Richard J. Daemer - Washington DC
Stephen M. Feinstone - Washington DC
Ian D. Gust - Fairfield, AU
Robert H. Purcell - Boyds MD

The United States of America as represented by the Secretary of the
Department of Health & Human Services - Washington DC

C12N 708, A61K 3912

435237

Human hepatitis A virus (HAV), taken directly from human clinical specimens, can be isolated and serially passaged in primary African green monkey kidney (AGMK) cell cultures. This strain induced antibody to HAV in inoculated chimpanzees and is useful for vaccine.

4615886, Oct 7, 1986

May 18, 1984

6/611752

Robert H. Purcell - Boyds MD
Stephen M. Feinstone - Washington DC

The United States of America as represented by the Secretary of the
Department of Health & Human Services - Washington DC

A61K 3514

424101

A method of inactivating a lipid virus contained in a dry protein carrier by contacting said virus-containing protein carrier for an abbreviated period of time at from 4. degree. -40. degree. C. with a composition including a halohydrocarbon treating agent and water dissolved in said treating agent. Preferred lipid viruses are Hepatitis B virus (HBV) and non-A, non-B Hepatitis (NANBH) virus.

RE37381, Sep 18, 2001

Sep 6, 1995

8/673408

Robert H. Purcell - Boyds MD
John R. Ticehurst - Kensington MD
Jeffrey I. Cohen - Silver Spring MD
Suzanne U. Emerson - Rockville MD
Stephen M. Feinstone - Washington DC
Richard J. Daemer - Kensington MD
Ian D. Gust - Ivanhoe, AU

The United States of America as represented by the Department of Health and
Human Services - Washington DC

A61K 3929, C12N 708, C07H 2104

4242261

The present invention provides an attenuated hepatitis A virus useful as a vaccine.